IRIS UniCatt

Evoli Stampanoni-B, Amelia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.788
AS - Asia 4.773
EU - Europa 4.641
SA - Sud America 1.016
Continente sconosciuto - Info sul continente non disponibili 237
AF - Africa 147
OC - Oceania 22
Totale 18.624
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.553
SG - Singapore 2.107
CN - Cina 1.226
DE - Germania 1.205
BR - Brasile 785
SE - Svezia 746
IT - Italia 573
UA - Ucraina 433
FR - Francia 427
VN - Vietnam 381
GB - Regno Unito 243
IE - Irlanda 231
PL - Polonia 210
IN - India 190
FI - Finlandia 154
ID - Indonesia 149
BD - Bangladesh 138
JP - Giappone 128
RU - Federazione Russa 128
CA - Canada 110
HK - Hong Kong 100
TR - Turchia 85
AR - Argentina 64
MX - Messico 56
NL - Olanda 56
IQ - Iraq 54
EC - Ecuador 48
BE - Belgio 47
ES - Italia 47
CI - Costa d'Avorio 35
CL - Cile 33
PK - Pakistan 32
ZA - Sudafrica 30
AT - Austria 28
VE - Venezuela 26
CO - Colombia 23
RO - Romania 23
KE - Kenya 21
AU - Australia 20
IL - Israele 20
UZ - Uzbekistan 20
PE - Perù 17
SA - Arabia Saudita 17
KR - Corea 14
AE - Emirati Arabi Uniti 12
CR - Costa Rica 12
JM - Giamaica 12
JO - Giordania 12
LT - Lituania 12
OM - Oman 12
CH - Svizzera 11
EG - Egitto 11
MA - Marocco 11
TN - Tunisia 11
AZ - Azerbaigian 10
BG - Bulgaria 10
PY - Paraguay 10
IR - Iran 9
MY - Malesia 9
DZ - Algeria 8
HN - Honduras 8
CZ - Repubblica Ceca 7
GR - Grecia 7
PT - Portogallo 7
BZ - Belize 6
PH - Filippine 6
TH - Thailandia 6
A2 - ???statistics.table.value.countryCode.A2??? 5
KG - Kirghizistan 5
KZ - Kazakistan 5
LB - Libano 5
NI - Nicaragua 5
PR - Porto Rico 5
UY - Uruguay 5
AO - Angola 4
BO - Bolivia 4
DK - Danimarca 4
EU - Europa 4
HU - Ungheria 4
LK - Sri Lanka 4
LU - Lussemburgo 4
NO - Norvegia 4
PA - Panama 4
AL - Albania 3
BY - Bielorussia 3
DO - Repubblica Dominicana 3
ET - Etiopia 3
GA - Gabon 3
GT - Guatemala 3
KH - Cambogia 3
LV - Lettonia 3
MD - Moldavia 3
TT - Trinidad e Tobago 3
BB - Barbados 2
CY - Cipro 2
MT - Malta 2
MU - Mauritius 2
NG - Nigeria 2
NP - Nepal 2
NZ - Nuova Zelanda 2
Totale 18.367
Salva come PNG Salva come JPEG
Città #
Singapore 1.116
Ashburn 946
Chandler 891
San Jose 604
Jacksonville 286
Beijing 253
San Mateo 230
Dublin 221
New York 218
Warsaw 174
Wilmington 158
Ann Arbor 154
Los Angeles 146
Nanjing 141
Houston 139
Jakarta 135
Ho Chi Minh City 127
Lauterbourg 125
Dearborn 116
Woodbridge 114
Boston 107
Tokyo 100
Dallas 99
Hong Kong 97
Cattolica 96
Hanoi 96
Chicago 90
Milan 85
Frankfurt am Main 81
Hefei 80
Princeton 71
Redwood City 69
São Paulo 69
Moscow 66
Rome 64
Lawrence 61
Santa Clara 59
Cambridge 58
North Bergen 57
Seattle 57
Buffalo 56
Nürnberg 53
Marseille 50
Munich 50
Fairfield 49
Bremen 46
Izmir 46
Nanchang 45
London 44
Fuzhou 42
Hangzhou 41
Brussels 38
Shanghai 38
Redmond 37
Abidjan 35
Nuremberg 34
Tianjin 32
Boardman 30
Mountain View 30
Brooklyn 29
Denver 28
Helsinki 28
Orem 28
Atlanta 27
Council Bluffs 27
Shenyang 27
Montreal 26
Zhengzhou 26
Norwalk 25
Chennai 24
Hebei 24
San Francisco 24
Amsterdam 23
Changsha 23
Düsseldorf 23
Paris 23
Turku 23
Bar Harbor 22
Des Moines 21
Phoenix 21
Rio de Janeiro 21
Toronto 21
Kunming 20
Mexico City 20
Porto Alegre 20
Belo Horizonte 19
Nairobi 19
Stockholm 19
Tashkent 19
Washington 18
Baghdad 17
Haiphong 17
Kent 17
Fortaleza 16
Leawood 16
Philadelphia 16
Poplar 16
The Dalles 16
Brasília 15
Guayaquil 15
Totale 9.531
Salva come PNG Salva come JPEG
Nome #
International consensus guidance for management of myasthenia gravis: Executive summary 371
Single-centre 40-year results of redo operation for recurrent thymomas. 249
Cognitive dysfunction in mice with passively induced MuSK antibody seropositive myasthenia gravis 249
PTPN22 and myasthenia gravis: replication in an Italian population and meta-analysis of literature data 243
Myasthenia gravis 243
Thirty-five-year follow-up analysis of clinical and pathologic outcomes of thymoma surgery. 241
Hypoglossal palsy and coeliac disease: an uncommon presentation for a common disease? 217
Thymopoiesis, regulatory T cells, and TCRVbeta expression in thymoma with and without myasthenia gravis, and modulatory effects of steroid therapy 214
Thymectomy in myasthenia gravis: proposal for a predictive score of postoperative myasthenic crisis. 211
Novel prognostic groups in thymic epithelial tumors: assessment of risk and therapeutic strategy selection. 208
Poly-autoimmunity in patients with myasthenia gravis: A single-center experience 208
T cell repertoire in DQ5-positive MuSK-positive myasthenia gravis patients 207
Long-Lasting Rituximab-Induced Reduction of Specific—But Not Total—IgG4 in MuSK-Positive Myasthenia Gravis 202
Thymoma in patients with MG: characteristics and long-term outcome 199
Distinctive clinical and neuroimaging characteristics of longitudinally extensive transverse myelitis associated with aquaporin-4 autoantibodies 198
Flow Cytofluorimetric Analysis of Anti-LRP4 (LDL Receptor-Related Protein 4) Autoantibodies in Italian Patients with Myasthenia Gravis 194
SFEMG: A piece in the diagnostic puzzle of myasthenia 190
Overcoming challenges in the diagnosis and treatment of myasthenia gravis 185
When myasthenia gravis is not all. 183
Overcoming challenges in the diagnosis and treatment of myasthenia gravis 183
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study 183
A Genome-wide Association Study of Myasthenia Gravis 182
An Italian Neurology Outpatient Clinic Facing SARS-CoV-2 Pandemic: Data From 2,167 Patients 181
Human Leukocyte Antigen Class II associations in late-onset Myasthenia Gravis 180
Remission of myasthenia gravis with MuSK antibodies during ruxolitinib treatment 177
Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders 175
Concordance between radioimmunoassay and fixed cell-based assay in subjects without myasthenia gravis: optimizing the diagnostic approach 172
Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis 169
3,4-Diaminopyridine may improve myasthenia gravis with MuSK antibodies 168
Serological Immunoglobulin-Free Light Chain Profile in Myasthenia Gravis Patients 168
HLA class II allele analysis in MuSK-positive myasthenia gravis suggests a role for DQ5. 166
Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. 165
Myasthenia gravis with antibodies to MuSK: an update 165
A b3 type-thymoma in a 7-year-old child with myasthenia gravis 163
Response to therapy in myasthenia gravis with anti-MuSK antibody 159
Characterization of B cells in muscle-specific kinase antibody myasthenia gravis 155
Acetylcholine receptor antibody positivity rate in ocular myasthenia gravis: a matter of age? 155
Thymectomy in myasthenia gravis via original video-assisted infra-mammary cosmetic incision and median sternotomy: long-term results in 180 patients. 152
Clinical characteristics and outcome of patients with autoimmune encephalitis: clues for paraneoplastic etiology 150
Ocular palsies in the absence of other neurological or ocular symptoms: analysis of 105 cases 149
An Italian Neurology Outpatient Clinic Facing SARS-CoV-2 Pandemic: Data From 2,167 Patients 148
Anti-AChR-negative myasthenia gravis: clinical and immunological features 147
Clinical and immunological characteristics of the spectrum of GFAP autoimmunity: a case series of 22 patients 147
Determinants of cognitive impairment in elderly myasthenia gravis patients 145
BAFF serum levels in myasthenia gravis: effects of therapy 144
Anti-acetylcholinesterase antibodies associate with ocular myasthenia gravis. 144
Prognostic grading after complete resection for thymic malignancies 143
International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update 143
Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: A systematic review and meta-analysis 141
Pattern of ocular involvement in myasthenia gravis with MuSK antibodies 141
Multiple paraneoplastic diseases associated with thymoma. 140
Diagnostic features and subtyping of thymoma lymph node metastases 140
Myasthenia gravis with presynaptic neurophysiological signs: Two case reports and literature review 138
Disease specific enrichment of circulating let-7 family microRNA in MuSK+ myasthenia gravis 138
Identification of genetic risk loci and prioritization of genes and pathways for myasthenia gravis: A genome-wide association study 136
Immunosuppressive therapies in myasthenia gravis 135
Clinical features and outcome of patients with autoimmune cerebellar ataxia evaluated with the Scale for the Assessment and Rating of Ataxia 135
Comment on "Cutting edge: human CD4-CD8- thymocytes express FOXP3 in the absence of a TCR". 134
Thymectomy in myasthenia gravis via original video-assisted infra-mammary cosmetic incision and median sternotomy: long term results in 180 patients. 134
The difficulty in confirming clinical diagnosis of Myasthenia Gravis in a seronegative patient: a possible neurophysiological approach 133
Epidemiological evidence for a hereditary contribution to myasthenia gravis: A retrospective cohort study of patients from North America 132
Clinical heterogeneity of seronegative myasthenia gravis 131
Management challenges in muscle-specific tyrosine kinase myasthenia gravis. 131
Overcoming challenges in the diagnosis and treatment of myasthenia gravis 131
Cancer Frequency in MuSK Myasthenia Gravis and Histological Evidence of Paraneoplastic Etiology 129
Rituximab in myasthenia gravis: a "to be or not to be" inhibitor of T cell function 128
Tumour necrosis factor beta gene polymorphisms in myasthenia gravis 127
Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis 126
Guidelines for treatment of autoimmune neuromuscular transmission disorders. 125
Thymic epithelial tumors express vascular endothelial growth factors and their receptors as potential targets of antiangiogenic therapy: a tissue micro array-based multicenter study 122
In sickness and in health: when myasthenia gravis is a conjugal matter 121
Reliability of SFEMG in diagnosing myasthenia gravis: Sensitivity and specificity calculated on 100 prospective cases. 120
Acquired myasthenia gravis in childhood. 119
Lower motor neuron involvement in longitudinally extensive transverse myelitis with and without aquaporin-4 antibodies 119
Comparison of Fixed and Live Cell-Based Assay for the Detection of AChR and MuSK Antibodies in Myasthenia Gravis 117
Spontaneous recovery from anti-NMDAR encephalitis 117
The detection of neural autoantibodies in patients with antiepileptic-drug-resistant epilepsy predicts response to immunotherapy 116
Safety and tolerability of SARS-Cov-2 vaccination in patients with myasthenia gravis: A multicenter experience 115
Thymectomy in the treatment of myasthenia gravis: report of 247 patients 114
Positive response to therapy in a patient with a seropositive paraneoplastic cerebellar degeneration and an endometrioid carcinoma of the vesicovaginal septum 113
Imatinib mesylate in thymic epithelial malignancies. 112
Thymoma recurrences in myasthenia gravis patients 112
IL-1 genes in myasthenia gravis: IL-1A -889 polymorphism associated with sex and age of disease onset 112
Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study 111
Course and treatment of myasthenia gravis during pregnancy 111
Early-onset myasthenia gravis: clinical characteristics and response to therapy 111
Molecular genetic alterations in egfr CA-SSR-1 microsatellite and egfr copy number changes are associated with aggressiveness in thymoma 110
Myasthenia gravis during interferon alfa therapy 108
Neurophysiological challenges in myasthenia gravis associated with MuSK antibodies: a case report 108
A practical guide to the recognition and management of myasthenia gravis 107
Italian recommendations for Lambert-Eaton myasthenic syndrome (LEMS) management. 107
SHP2 inhibitor protects AChRs from effects of myasthenia gravis MuSK antibody 107
Anti-MuSK antibodies: Correlation with myasthenia gravis severity 107
Controversies in Ocular Myasthenia Gravis 107
Myasthenia gravis and associated autoimmune diseases 105
Antibody-phenotype correlation in stiff-person syndrome 105
Benefit and danger from immunotherapy in myasthenia gravis 105
Minimal manifestation status and prednisone withdrawal in the MGTX trial 103
EFNS/ENS Guidelines for the treatment of ocular myasthenia. 101
Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. 101
Totale 15.138
Salva come PNG Salva come JPEG
Categoria #
all - tutte 75.417
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 75.417
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.179 0 97 32 69 97 45 34 197 62 78 182 286
2022/20232.629 313 361 205 387 155 311 256 217 273 41 70 40
2023/20241.174 53 318 47 84 46 163 86 74 11 27 132 133
2024/20252.252 54 90 181 60 171 66 72 119 376 172 455 436
2025/20266.290 954 176 358 805 1.149 302 970 288 432 439 165 252
2026/2027857 290 567 0 0 0 0 0 0 0 0 0 0
Totale 18.624